Form 4: Seres Therapeutics CEO Eric Shaff Reports Stock Transactions
SEC Form 4
Seres Therapeutics CEO Eric Shaff reports the vesting and sale of restricted stock units to cover taxes.
Summary
- On October 27, 2024, Eric Shaff, CEO and President of Seres Therapeutics, had 27,837 restricted stock units (RSUs) vest and settle.
- These RSUs represent a contingent right to receive one share of Seres Therapeutics common stock each.
- Shaff also sold 8,748 shares of common stock on October 28, 2024, at a weighted average price of $0.6901 per share.
- The sales were executed under a Rule 10b5-1 trading plan adopted on April 4, 2023, to cover taxes related to the vesting of the RSUs.
- Following these transactions, Shaff directly owns 165,082 shares of Seres Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The filing simply reports stock transactions by the CEO, which are part of a pre-arranged plan. There's no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency to investors about the trading activities of those with privileged information.
Comparison to Industry Standards
- Comparing Eric Shaff's transactions to those of CEOs at similar biotech companies like Synlogic or Finch Therapeutics would provide context.
- For example, if other CEOs are also selling shares under 10b5-1 plans to cover taxes, it might be considered a normal practice.
- However, if other CEOs are increasing their holdings, it could suggest a stronger belief in their company's future prospects.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholders if it creates downward pressure on the stock price, although the impact is likely minimal given the pre-planned nature of the sales.
Key Dates
| Date | Description |
|---|---|
| 2023-02-03 | Reporting person was granted an award of 55,675 restricted stock units (RSUs). |
| 2023-04-04 | Rule 10b5-1 instruction adopted by the reporting person. |
| 2023-04-27 | Initial Milestone Date: The Issuer's Administrator determined that the performance criteria for the first installment were met. |
| 2023-10-27 | First installment of RSUs (27,838) vested and settled. |
| 2024-10-27 | Remaining 27,837 RSUs vested and settled. |
| 2024-10-27 | Eric Shaff had 27,837 restricted stock units (RSUs) vest. |
| 2024-10-28 | Eric Shaff sold 8,748 shares of common stock at an average price of $0.6901. |
| 2024-10-29 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.